
|Articles|April 16, 2015
- Melanoma (Issue 4)
- Volume 4
- Issue 1
The Development of T-VEC for Melanoma
Author(s)Kevin B. Kim, MD
Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses the outlook for T-VEC for the treatment of patients with melanoma.
Advertisement
Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses the outlook for T-VEC for the treatment of patients with melanoma.
<<<
Articles in this issue
almost 11 years ago
Unprecedented Response Rates Seen With Ipilimumab Plus Nivolumab in Melanomaalmost 11 years ago
Toxicity of Immunotherapies in Melanomaalmost 11 years ago
Comparing Two Doses of Ipilimumabalmost 11 years ago
New Standards Needed to Lessen Surgery Delays in Melanomaalmost 11 years ago
Neoantigens for Personalized Immunotherapy May Boost Melanoma Treatmentalmost 11 years ago
Gene Removal May Pose Future Treatment in Advanced Melanomaalmost 11 years ago
The Role of Macrophages in BRAF Inhibitor ResistanceAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















